Skip to main content

Advertisement

Log in

Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism

  • NEURO-EPIDEMIOLOGY
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Higher coffee consumption has been associated with reduced dementia risk, yet with inconsistencies across studies. CYP1A2 polymorphisms, which affects caffeine metabolism, may modulate the association between coffee and the risk of dementia and Alzheimer’s disease (AD). We included 5964 participants of the Three-City Study (mean age 74 years-old), free of dementia at baseline when they reported their daily coffee consumption, with available genome-wide genotyping and followed for dementia over a median of 9.0 (range 0.8–18.7) years. In Cox proportional-hazards models, the relationship between coffee consumption and dementia risk was modified by CYP1A2 polymorphism at rs762551 (p for interaction = 0.034). In multivariable-adjusted models, coffee intake was linearly associated with a decreased risk of dementia among carriers of the C allele only (“slower caffeine metabolizers”; HR for 1-cup increased [95% CI] 0.90 [0.83–0.97]), while in non-carriers (“faster caffeine metabolizers”), there was no significant association but a J-shaped trend toward a decrease in dementia risk up to 3 cups/day and increased risk beyond. Thus, compared to null intake, drinking ≥ 4 cups of coffee daily was associated with a reduced dementia risk in slower but not faster metabolizers (HR [95% CI] for ≥ 4 vs. 0 cup/day = 0.45 [0.25–0.80] and 1.32 [0.89–1.96], respectively). Results were similar when studying AD and another CYP1A2 candidate polymorphism (rs2472304), but no interaction was found with CYP1A2 rs2472297 or rs2470893. In this cohort, a linear association of coffee intake to lower dementia risk was apparent only among carriers of CYP1A2 polymorphisms predisposing to slower caffeine metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimer’s Dis. 2009;17:661–80.

    Article  CAS  Google Scholar 

  2. Wu L, Sun D, He Y. Coffee intake and the incident risk of cognitive disorders: a dose–response meta-analysis of nine prospective cohort studies. Clin Nutr. 2017;36:730–6.

    Article  PubMed  Google Scholar 

  3. Larsson SC, Orsini N. Coffee consumption and risk of dementia and Alzheimer’s disease: a dose-response meta-analysis of prospective studies. Nutrients. 2018;10: 1501.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163 C > A polymorphism. Eur J Clin Pharmacol. 2010;66:697–703.

    Article  CAS  PubMed  Google Scholar 

  5. Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol. 2011;18:756–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kapellou A, King A, Graham CAM, Pilic L, Mavrommatis Y. Genetics of caffeine and brain-related outcomes—a systematic review of observational studies and randomized trials. Nutr Rev. 2023. https://doi.org/10.1093/nutrit/nuad029/7111264.

    Article  PubMed  Google Scholar 

  7. Cornelis MC, Bennett DA, Weintraub S, Schneider JA, Morris MC. Caffeine consumption and dementia: are lewy bodies the link? Ann Neurol. 2022;91:834–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet. 2016;25:5472–82.

    CAS  PubMed  Google Scholar 

  9. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Larsson SC, Woolf B, Gill D. Plasma caffeine levels and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomization study. Nutrients. 2022;14: 1697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Nordestgaard AT, Nordestgaard BG, Frikke-Schmidt R, Juul Rasmussen I, Bojesen SE. Self-reported and genetically predicted coffee consumption and smoking in dementia: a Mendelian randomization study. Atherosclerosis. 2022;348:36–43.

    Article  CAS  PubMed  Google Scholar 

  12. Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, et al. Coffee intake and decreased amyloid pathology in human brain. Transl Psychiatry. 2019;9:1–10.

    Article  Google Scholar 

  13. Pham K, Mulugeta A, Zhou A, O’Brien JT, Llewellyn DJ, Hyppönen E. High coffee consumption, brain volume and risk of dementia and stroke. Nutr Neurosci. 2022;25:2111–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The Three-City Study is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut de Santé Publique et Développement of the Victor Segalen Bordeaux 2 University and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3 C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, Regional Governments of Aquitaine and Bourgogne, Fondation de France, Ministry of Research-INSERM Programme “Cohortes et collections de données biologiques”, French National Research Agency COGINUT ANR-06-PNRA-005, the Fondation Plan Alzheimer (FCS 2009–2012), and the Caisse Nationale pour la Solidarité et l’Autonomie (CNSA).

Author information

Authors and Affiliations

Authors

Contributions

Catherine Helmer, Claudine Berr and Stephanie Debette contributed to the Three-City study conception, design and data collection. Statistical analyses were performed by Sophie Lefèvre-Arbogast under the supervision of Cécilia Samieri. The first draft of the manuscript was written by Sophie Lefèvre-Arbogast and Cécilia Samieri, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Sophie Lefèvre-Arbogast.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interest to disclose.

Ethics approval

The Consultative Committee for the Protection of Persons participating in Biomedical Research at Kremlin-Bicêtre University Hospital (Paris, France) approved the Three-City study protocol (CPP no 99-28, June 10, 1999).

Consent to participate

All participants provided written informed consent.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 1163.2 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lefèvre-Arbogast, S., Helmer, C., Berr, C. et al. Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism. Eur J Epidemiol 39, 81–86 (2024). https://doi.org/10.1007/s10654-023-01060-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-023-01060-x

Keywords

Navigation